Motiv8 Investments LLC Decreases Position in Heron Therapeutics, Inc. (NASDAQ:HRTX)

Motiv8 Investments LLC cut its holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 10.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 69,245 shares of the biotechnology company’s stock after selling 8,401 shares during the period. Motiv8 Investments LLC’s holdings in Heron Therapeutics were worth $106,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of HRTX. Cutter & CO Brokerage Inc. purchased a new position in shares of Heron Therapeutics in the third quarter valued at $39,000. Y Intercept Hong Kong Ltd purchased a new position in Heron Therapeutics during the 3rd quarter valued at about $39,000. Capstone Investment Advisors LLC purchased a new position in Heron Therapeutics during the 3rd quarter valued at about $45,000. King Wealth Management Group increased its position in shares of Heron Therapeutics by 52.3% during the third quarter. King Wealth Management Group now owns 23,299 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 8,000 shares during the period. Finally, Glenmede Trust Co. NA lifted its holdings in shares of Heron Therapeutics by 49.6% in the third quarter. Glenmede Trust Co. NA now owns 31,903 shares of the biotechnology company’s stock worth $63,000 after buying an additional 10,578 shares in the last quarter. Institutional investors own 80.01% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on HRTX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $4.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, December 4th. StockNews.com lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 29th.

Heron Therapeutics Trading Up 1.8 %

Shares of Heron Therapeutics stock opened at $1.71 on Thursday. The firm has a market capitalization of $260.08 million, a PE ratio of -9.50 and a beta of 1.60. Heron Therapeutics, Inc. has a 12 month low of $1.04 and a 12 month high of $3.93. The business’s 50-day moving average price is $1.66 and its 200-day moving average price is $1.71.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.